Schirmer, Markus Anton

[["dc.bibliographiccitation.firstpage","59"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Pharmacogenetics and Genomics"],["dc.bibliographiccitation.lastpage","71"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Haberl, M."],["dc.contributor.author","Suk, A."],["dc.contributor.author","Kamdem, L. K."],["dc.contributor.author","Klein, K."],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Nurnberg, P."],["dc.contributor.author","Zanger, Ulrich M."],["dc.contributor.author","Wojnowski, Leszek"],["dc.date.accessioned","2018-11-07T10:40:54Z"],["dc.date.available","2018-11-07T10:40:54Z"],["dc.date.issued","2006"],["dc.description.abstract","Cytochrome P450 3A enzymes (CYP3A) play a major role in the metabolism of steroid hormones, drugs and other chemicals, including many carcinogens. The individually variable CYP3A expression, which remains mostly unexplained, has been suggested to affect clinical phenotypes. We investigated the CYP3A locus in five ethnic groups. The degree of linkage disequilibrium (LD) differed among ethnic groups, but the most common alleles of the conserved LD regions were remarkably similar. Non-African haplotypes are few; for example, only four haplotypes account for 80% of common European Caucasian alleles. Large LD blocks of high frequencies were suggestive of selection. Accordingly, European Caucasian and Asian cohorts each contained a block of single nucleotide polymorphism (SN Ps) with very high P excess values. The overlap between these blocks in these two groups contained only two of the investigated 26 SNPs and one of them was the CYP3A4 1B allele. The region centromeric of CYP3A4 lB exhibited high haplotype homozygosity in European Caucasians as opposed to Africa n-Americans. CYP3A4 lB showed a moderate effect on CYP3A4 mRNA and protein expression, as well as on CYP3A activity assessed as (V)max of testosterone 6 beta-hydroxylation in a liver bank. Our data are consistent with a functional relevance of CYP3A4 1B and with selection against this allele in non-African populations. The elimination of CYP3A4 1B involved different parts of the CYP3A locus in European Caucasians and Asians. Because CYP3A4 is involved in the vitamin D metabolism, rickets may have been the underlying selecting factor. Pharmacogenetics and Genomics 16:59-71. (c) 2006 Lippincott Williams & Wilkins."],["dc.identifier.isi","000234277400008"],["dc.identifier.pmid","16344723"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46413"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1744-6872"],["dc.title","Genetic signature consistent with selection against the CYP3A4 1B allele in non-African populations"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2328"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Cancer Research"],["dc.bibliographiccitation.lastpage","2338"],["dc.bibliographiccitation.volume","70"],["dc.contributor.author","Hoffmann, Marion"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Kreuz, Markus"],["dc.contributor.author","Ziepert, Marita"],["dc.contributor.author","Wojnowski, Leszek"],["dc.contributor.author","Kube, Dieter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T08:45:02Z"],["dc.date.available","2018-11-07T08:45:02Z"],["dc.date.issued","2010"],["dc.description.abstract","NAD(P)H oxidase is a major endogenous source of reactive oxygen species (ROS). ROS may not only be involved in carcinogenesis but also in efficacy of chemotherapeutic agents like doxorubicin. By a comprehensive genotyping approach covering 48 genetic polymorphisms (single-nucleotide polymorphisms) in five subunits of phagocytic NAD(P) H oxidase, we asked whether they affect gene expression, enzymatic activity, and outcome of CHO(E) P chemotherapy. A highly consistent effect was observed for the CYBA 640A>G variant. In peripheral blood granulocytes of 125 healthy volunteers, the G allele of 640A>G was associated with lower NAD(P) H oxidase activity (P = 0.006). Moreover, the G allele was associated with lower mRNA and protein expression (both P = 0.02). Of clinical importance, the outcome of patients suffering from non-Hodgkin lymphoma and treated with CHO(E) P regimen was dependent on the CYBA 640A>G polymorphism. In an exploratory study (n = 401), carriers of 640GG had an event-free survival (EFS) risk ratio of 1.95 [95% confidence interval (95% CI), 1.31-2.90; P = 0.001] compared with 640AA. In a confirmatory set (n = 477), the risk ratios were 1.53 (1.04-2.25, P = 0.03). The complete set of 878 patients showed a relative risk of 1.72 (1.30-2.26) and 1.59 (1.14-2.21) for EFS and overall survival, respectively. Further molecular-biological experiments showed lower expression and reduced stability of transcripts with the G allele in lymphoblastoid cell lines. Transfection of allele-specific plasmids into HEK293 cells elicited lower activity for the G allele in a luciferase reporter gene construct. Thus, CYBA 640A>G was shown to be a functional polymorphism with possible consequences for patients receiving CHO(E) P chemotherapy and might have further implications for other ROS-mediated modalities. Cancer Res; 70(6); 2328-38. (C) 2010 AACR."],["dc.identifier.doi","10.1158/0008-5472.CAN-09-2388"],["dc.identifier.isi","000278485900020"],["dc.identifier.pmid","20215507"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20334"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","0008-5472"],["dc.title","A Functional Polymorphism in the NAD(P)H Oxidase Subunit CYBA Is Related to Gene Expression, Enzyme Activity, and Outcome in Non-Hodgkin Lymphoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","323"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","British Journal of Clinical Pharmacology"],["dc.bibliographiccitation.lastpage","335"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Vormfelde, Stefan Viktor"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Hagos, Yohannes"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Engelhardt, Sabine"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Burckhardt, Gerhard"],["dc.contributor.author","Nuernberg, Peter"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T09:17:38Z"],["dc.date.available","2018-11-07T09:17:38Z"],["dc.date.issued","2006"],["dc.description.abstract","Aims To investigate the association between torsemide renal clearance and genetic variation in the basolaterally expressed renal organic anion transporters OAT1 and OAT3 and in the luminally situated OAT4. Methods We analysed 22 polymorphisms in the OAT coding genes SLC22A6, SLC22A8 and SLC22A11 and their haplotypes and measured torsemide renal clearance in 95 healthy men. In addition, the effect of torsemide on the OAT-mediated transport was studied in vitro. Results In stably transfected HEK293 cells torsemide (100 mu m) inhibited the uptake by human OAT1, OAT3 and OAT4 by 63.1, 58.1 and 68.0%, respectively. Torsemide renal clearance ranged from 6.5 to 43.1 ml min(-1) with a log-normal distribution and a geometric mean of 15.6 ml min(-1) (15.0-16.1 +/- SEM). No clear outlier group was observed. AA carriers of the polymorphism rs11231809 in SLC22A11 had a torsemide renal clearance of 13.3 ml min(-1) (12.7-13.9) compared with 15.1 ml min(-1) (14.5-15.8) in AT and 18.0 ml min(-1) (16.7-19.5) in TT carriers (P = 0.002). The two most frequent haplotypes at SLC22A11 showed an association with torsemide renal clearance. Homozygous carriage of these two haplotypes resulted in renal clearances of 21.2 ml min(-1) (19.0-23.7) and 11.8 ml min(-1) (10.5-13.5), respectively. No association between reanl clearance and genetic variation in SLC22A6 or SLC22A8 was observed. Conclusions Genetic variation in the gene encoding the luminally expressed OAT4 rather than in the basolaterally expressed OATs may affect the renal clearance of torsemide."],["dc.identifier.doi","10.1111/j.1365-2125.2006.02655.x"],["dc.identifier.isi","000239694000011"],["dc.identifier.pmid","16934049"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28213"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing"],["dc.relation.issn","0306-5251"],["dc.title","Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Christiansen, H."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Mergler, Caroline Patricia Nadine"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.date.accessioned","2018-11-07T08:55:29Z"],["dc.date.available","2018-11-07T08:55:29Z"],["dc.date.issued","2011"],["dc.format.extent","49"],["dc.identifier.isi","000291236200133"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22914"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","TGFB1 Pro25 allele as a risk marker for higher-grade acute Organ toxicity (CTC >= Grad2) during neoadjuvant Chemoradiotherapy in patients with locally advanced Rectal cancer (UICC Stage II/III)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","557"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Human Mutation"],["dc.bibliographiccitation.lastpage","565"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Kulle, Bettina"],["dc.contributor.author","Schirmer, M"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Suk, A."],["dc.contributor.author","Becker, C."],["dc.contributor.author","Tzvetkov, Mladen"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Bickeböller, Heike"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Nürnberg, Peter"],["dc.contributor.author","Wojnowski, Leszek"],["dc.date.accessioned","2017-09-07T11:54:27Z"],["dc.date.available","2017-09-07T11:54:27Z"],["dc.date.issued","2005"],["dc.description.abstract","The prospect of SNP-based genomewide association analysis has been extensively discussed, but practical experiences remain limited. We performed an association study using a recently developed array of 11,555 SNPs distributed throughout the human genome. A total of 104 DNA samples were hybridized to these chips with an average call rate of 97% (range 85.3-98.6%). The resulting genomewide scans were applied to distinguish between carriers and noncarriers of 37 test variants, used as surrogates for monogenic disease traits. The test variants were not contained in the chip and had been determined by other methods. Without adjustment for multiple testing, the procedure detected 24% of the test variants, but the positive predictive value was low (2%). Adjustment for multiple testing eliminated most false-positive associations, but the share of true positive associations decreased to 10-12%. We also simulated fine-mapping of susceptibility loci by restricting testing to the immediate neighborhood of test variants (+/- 5 Mb). This increased the proportion of correctly identified test variants to 22-27%. Simulation of a bigenic inheritance reduced the sensitivity to 1%. Similarly adverse effect had reduction of allelic penetrance. In summary, we demonstrate the feasibility and considerable specificity of SNP array based association studies to detect variants underlying monogenic, highly penetrant traits. The outcome is affected by allelic frequencies of chip SNPs, by the ratio between simulated \"cases\" and \"controls,\" and by the degree of linkage disequilibrium. A major improvement is expected from raising the density of the SNP array. (c) 2005 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/humu.20174"],["dc.identifier.gro","3143839"],["dc.identifier.isi","000229456700007"],["dc.identifier.pmid","15880731"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1397"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley-liss"],["dc.relation.issn","1059-7794"],["dc.title","Application of genomewide SNP arrays for detection of simulated susceptibility loci"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2805"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Leu, Martin"],["dc.contributor.author","Riebeling, Theresa"],["dc.contributor.author","Dröge, Leif Hendrik"],["dc.contributor.author","Hubert, Laura"],["dc.contributor.author","Guhlich, Manuel"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.date.accessioned","2021-07-05T15:00:42Z"],["dc.date.available","2021-07-05T15:00:42Z"],["dc.date.issued","2021"],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.abstract","Despite excellent loco-regional control by multimodal treatment of locally advanced rectal cancer, a substantial portion of patients succumb to this disease. As many treatment effects are mediated via reactive oxygen species (ROS), we evaluated the effect of single nucleotide polymorphisms (SNPs) in ROS-related genes on clinical outcome. Based on the literature, eight SNPs in seven ROS-related genes were assayed. Eligible patients (n = 287) diagnosed with UICC stage II/III rectal cancer were treated multimodally starting with neoadjuvant radiochemotherapy (N-RCT) according to the clinical trial protocols of CAO/ARO/AIO-94, CAO/ARO/AIO-04, TransValid-A, and TransValid-B. The median follow-up was 64.4 months. The Ser326Cys polymorphism in the human OGG1 gene affected clinical outcome, in particular cancer-specific survival (CSS). This effect was comparable in extent to the ypN status, an already established strong prognosticator for patient outcome. Homozygous and heterozygous carriers of the Cys326 variant (n = 105) encountered a significantly worse CSS (p = 0.0004 according to the log-rank test, p = 0.01 upon multiple testing adjustment). Cox regression elicited a hazard ratio for CSS of 3.64 (95% confidence interval 1.70–7.78) for patients harboring the Cys326 allele. In a multivariable analysis, the effect of Cys326 on CSS was preserved. We propose the genetic polymorphism Ser326Cys as a promising biomarker for outcome in rectal cancer."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.3390/cancers13112805"],["dc.identifier.pii","cancers13112805"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87886"],["dc.language.iso","en"],["dc.notes.intern","DOI Import DOI-Import GROB-441"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","8-Oxoguanine DNA Glycosylase (OGG1) Cys326 Variant: Increased Risk for Worse Outcome of Patients with Locally Advanced Rectal Cancer after Multimodal Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","300"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Clinical Pharmacology & Therapeutics"],["dc.bibliographiccitation.lastpage","309"],["dc.bibliographiccitation.volume","82"],["dc.contributor.author","Vormfelde, Stefan Viktor"],["dc.contributor.author","Sehrt, Daniel"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Nuernberg, P."],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T10:58:47Z"],["dc.date.available","2018-11-07T10:58:47Z"],["dc.date.issued","2007"],["dc.description.abstract","There is little data on genetic predictors of loop diuretic efficacy in humans. Therefore, we investigated the diuretic effects of single oral doses of bumetanide, frusemide, and torsemide in a crossover study in 97 healthy Caucasians in relation to genetic variation in the renal sodium transporters NKCC2 (coded by SLC12A1), NCC (SLC12A3), and ENaC (three subunits coded by SCNN1A, SCNN1B, and SCNN1G). The NCC alanine 264 allele (Gly264Ala) and the most frequent SCNN1B haplotype were associated with stronger diuresis, indicating lower reabsorbing function of these alleles. The variant alleles of the tightly coupled polymorphisms rs5723 (Leu649Leu) and rs5729 in SCNN1G were associated with weaker diuresis, indicating higher activity. Extended haplotype homozygosity implied evolutionary selection of the NCC alanine 264 allele. In conclusion, acute diuretic effects of loop diuretics were affected by genetic variation in sodium transporters that, in the nephron, are located distally from NKCC2."],["dc.identifier.doi","10.1038/sj.clpt.6100131"],["dc.identifier.isi","000249062300012"],["dc.identifier.pmid","17460608"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50547"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0009-9236"],["dc.title","Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3754"],["dc.bibliographiccitation.issue","24"],["dc.bibliographiccitation.journal","Circulation"],["dc.bibliographiccitation.lastpage","3762"],["dc.bibliographiccitation.volume","112"],["dc.contributor.author","Wojnowski, Leszek"],["dc.contributor.author","Kulle, Bettina"],["dc.contributor.author","Schirmer, Markus"],["dc.contributor.author","Schlüter, Georg"],["dc.contributor.author","Schmidt, Albrecht"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Vonhof, Stefan"],["dc.contributor.author","Bickeböller, Heike"],["dc.contributor.author","Toliat, Mohammad Reza"],["dc.contributor.author","Suk, Eun-Kyung"],["dc.contributor.author","Tzvetkov, Mladen"],["dc.contributor.author","Kruger, Anke"],["dc.contributor.author","Seifert, Silvia"],["dc.contributor.author","Kloess, Marita"],["dc.contributor.author","Hahn, Heidi"],["dc.contributor.author","Loeffler, Markus"],["dc.contributor.author","Nürnberg, Peter"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Brockmöller, Jürgen"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.date.accessioned","2017-09-07T11:53:40Z"],["dc.date.available","2017-09-07T11:53:40Z"],["dc.date.issued","2005"],["dc.description.abstract","Background-A significant number of patients treated with anthracyclines develop cardiotoxicity (anthracycline-induced cardiotoxicity [ACT]), mainly presenting as arrhythmias (acute ACT) or congestive heart failure (chronic ACT). There are no data on pharmacogenomic predictors of ACT. Methods and Results-We genotyped participants of the German non-Hodgkin lymphoma study (NHL-B) who were followed up for the development of heart failure for a median of > 3 years. Single-nucleotide polymorphisms (SNPs) were selected from 82 genes with conceivable relevance to ACT. Of 1697 patients, 55 developed acute and 54 developed chronic ACT (cumulative incidence of either form, 3.2%). We detected 5 significant associations with polymorphisms of the NAD(P)H oxidase and doxorubicin efflux transporters. Chronic ACT was associated with a variant of the NAD(P)H oxidase subunit NCF4 (rs1883112, -212A -> G; symbols with right-pointing arrows, as edited? odds ratio [OR], 2.5; 95% CI, 1.3 to 5.0). Acute ACT was associated with the His72Tyr polymorphism in the p22phox subunit (rs4673; OR, 2.0; 95% CI, 1.0 to 3.9) and with the variant 7508T -> A (rs13058338; OR, 2.6; 95% CI, 1.3 to 5.1) of the RAC2 subunit of the same enzyme. In agreement with these results, mice deficient in NAD( P) H oxidase activity, unlike wild-type mice, were resistant to chronic doxorubicin treatment. In addition, acute ACT was associated with the Gly671Val variant of the doxorubicin efflux transporter multidrug resistance protein 1 (MRP1) (OR, 3.6; 95% CI, 1.6 to 8.4) and with the Val1188Glu-Cys1515Tyr (rs8187694-rs8187710) haplotype of the functionally similar MRP2 (OR, 2.3; 95% CI, 1.0 to 5.4). Polymorphisms in adrenergic receptors previously demonstrated to be predictive of heart failure were not associated with ACT. Conclusions-Genetic variants in doxorubicin transport and free radical metabolism may modulate the individual risk to develop ACT."],["dc.identifier.doi","10.1161/CIRCULATIONAHA.105.576850"],["dc.identifier.gro","3143774"],["dc.identifier.isi","000233901500014"],["dc.identifier.pmid","16330681"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/1325"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","0009-7322"],["dc.title","NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Experimental Dermatology"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Boeckmann, L."],["dc.contributor.author","Thoms, Kai Martin"],["dc.contributor.author","Gutzmer, Ralf"],["dc.contributor.author","Has, Cristina"],["dc.contributor.author","Kunz, M."],["dc.contributor.author","Kuschal, Christiane"],["dc.contributor.author","Laspe, Petra"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Struever, Diana"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.contributor.author","Emmert, Steffen"],["dc.date.accessioned","2018-11-07T08:32:03Z"],["dc.date.available","2018-11-07T08:32:03Z"],["dc.date.issued","2009"],["dc.format.extent","311"],["dc.identifier.isi","000263520200230"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17256"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell Publishing, Inc"],["dc.publisher.place","Malden"],["dc.relation.conference","36th Annual Meeting of the Arbeitsgemeinschaft-Dermatologishche-Forschung"],["dc.relation.eventlocation","Heidelberg, GERMANY"],["dc.relation.issn","0906-6705"],["dc.title","DNA repair host factors modulate side effects of temozolomide or dacarbazinemelanoma treatment rather than treatment efficacy and are determined by promoter methylation"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","European Journal of Clinical Pharmacology"],["dc.bibliographiccitation.volume","61"],["dc.contributor.author","Kuhne, A."],["dc.contributor.author","Kaiser, R."],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Muhlke, Sabine"],["dc.contributor.author","Niere, W."],["dc.contributor.author","Wasser, Katrin"],["dc.contributor.author","Overbeck, Tobias R."],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Meinecke, I."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Sezer, Orhan"],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T10:54:34Z"],["dc.date.available","2018-11-07T10:54:34Z"],["dc.date.issued","2005"],["dc.format.extent","712"],["dc.identifier.isi","000232696100099"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49596"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","7th Annual Congress of Clinical Pharmacology"],["dc.relation.eventlocation","Dresen, GERMANY"],["dc.relation.issn","0031-6970"],["dc.title","Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics of melphalan"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]